Chong Kun Dang launches Camtobell injection, camptothecin analogue topoisomerase I inhibitor

Published: 2004-03-04 07:00:00

Updated: 2004-03-04 07:00:00

Chong Kun Dang Pharmaceutical Co. said it launched Korea's 8th new drug Camtobell injection for the treatment of ovarian cancer (second-line therapy) and small-cell lung cancer (first-line therapy) on March 2, which was approved by Korea Food and Drug Administration in October of last year, as a ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK